Oncology Letters

Papers
(The H4-Index of Oncology Letters is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
[Corrigendum] Molecular heterogeneity of guanine nucleotide binding‑protein γ subunit 4 in left‑ and right‑sided colon cancer76
Synchronous primary colorectal mucinous adenocarcinoma and pancreatic ductal adenocarcinoma: A case report65
Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report63
Proteomics analysis reveals elevated RAB21 in serum‑derived extracellular vesicles from patients with follicular thyroid carcinoma55
Primary gingival diffuse large B‑cell lymphoma with muscle invasion: A case report54
Metastatic squamous cell carcinoma in the residual spleen diagnosed with emergency ultrasonography: A case report43
Prognostic value of circWWC3 as a novel survival‑related biomarker for clear cell renal cell carcinoma41
Immune checkpoint inhibitors with or without radiotherapy in metastatic non‑small cell lung cancer: A meta‑analysis and literature review41
Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin‑induced apoptosis in epithelial ovarian cancer40
Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis39
Primary osteosarcoma of the kidney: A case report39
Novel therapeutic strategies for non‑small cell lung cancer: Combination therapies with immune checkpoint inhibitors (Review)37
Upregulated miR‑378a‑3p expression suppresses energy metabolism and promotes apoptosis by targeting a GLUT‑1/ALDOA/PKM2 axis in esophageal carcinoma36
Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary study35
Multiple primary tumors in a patient with non‑small‑cell lung cancer harboring mutations in ERCC6 and LYL1: A case report33
Antitumor effects of plasma‑activated solution on a murine melanoma model in vivo and in vitro32
Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib29
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated28
Prediction and verification of the prognostic biomarker SLC2A2 and its association with immune infiltration in gastric cancer28
Prognostic value of moderate or massive ascites in patients with advanced gastric cancer27
Gastric carcinoma harbouring loss‑of‑function mutations in the PIK3R1, ATRX and RBM10 genes exhibits diverse histological features associated with EBV infection and TP53 in27
Function of SP1 in tumors and focused treatment approaches for immune evasion (Review)27
Comprehensive treatment for two patients with small cell neuroendocrine carcinoma of the liver: A case report and literature review27
Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)24
Investigation into the synergistic effect of atorvastatin combined with ultrasound stimulation for anti‑glioma therapy24
Meta‑analysis of the efficacy and safety of thoracic radiotherapy for extensive‑stage small cell lung cancer  in the era of immunotherapy24
Mechanism of action of Aloe vera against human papillomavirus‑positive head and neck squamous cell carcinoma24
0.084035158157349